About
Therapeutic Antibodies, CMO
Areas of Focus
Categories
Contract ManufacturingContract ManufacturingBiologics & BiopharmaceuticalContract ManufacturingContract ResearchContract ManufacturingContract ManufacturingAntibodyCg Cmc
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
92
By Phase
PHASE1: 2PHASE1/PHASE2: 1
By Status
COMPLETED: 2UNKNOWN: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Today
Hover over trial bars to see details
Recent Trials
NCT05540873Lead Sponsor
A Clinical Study of IL13Rα2 Targeted CAR-T in Patients With Malignant Glioma (MAGIC-I)
PHASE1Unknown
18 participants
Started: Jul 18, 2022 · Completed: Apr 30, 2024
NCT04368507Lead Sponsor
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patients Who Are Metastatic or Recurrent Colorectal Cancer Patients
PHASE1/PHASE2Completed
35 participants
Started: Aug 9, 2019 · Completed: Dec 21, 2021
NCT02499224Lead Sponsor
Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy
PHASE1Completed
39 participants
Started: Jul 13, 2015 · Completed: Jul 4, 2018
Locations (1)
Headquarters
Seoul, Korea
Map
Loading map...